Overview
This technology is a specialized protein export system for efficiently producing recombinant protein from a host cell while optimizing safety for use with live vector vaccines, and is related to that described in Docket Code JG-2001-022. The UMB inventors have engineered a genetically stabilized expression plasmid incorporating the protein of interest fused to a fully non-hemolytic mutant of the ClyA hemolysin derived from Salmonella enterica serovar Typhi. Used in a live-vector vaccine, this system allows the export of heterologous antigen for enhancement of vaccine immunogenicity.
Applications
Live vector vaccines
Advantages
Any hemolytic activity from ClyA has been removed while preserving efficient export of the fusion protein.
Stage of Development
Preliminary tests in a mouse model demonstrate enhanced immune response to a S. Typhi strain expressing the non-hemolytic ClyA fusion protein.
R&D Required
Full clinical development in conjunction with particular vaccine(s).
Licensing Potential
UMB seeks partners for further development and commercialization.
Contact Info
Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: [email protected]
Phone: (410) 706-2380